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Eﬀ ects of the introduction of new vaccines in Guinea-Bissau 
on vaccine coverage, vaccine timeliness, and child survival: 
an observational study
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Summary
Background In 2008, the GAVI Alliance funded the introduction of new vaccines (including pentavalent diphtheria-
tetanus-pertussis [DTP] plus hepatitis B and Haemophilus inﬂ uenzae type b antigens) in Guinea-Bissau. The 
introduction was accompanied by increased vaccination outreach services and a more restrictive wastage policy, 
including only vaccinating children younger than 12 months. We assessed coverage of all vaccines in the Expanded 
Program on Immunizations before and after the new vaccines’ introduction, and the implications on child survival.
Methods This observational cohort study used data from the Bandim Health Project, which has monitored vaccination 
status and mortality in randomly selected village clusters in Guinea-Bissau since 1990. We assessed the change in 
vaccination coverage using cohort data from children born in 2007 and 2009; analysed the proportion of children who 
received measles vaccine after 12 months of age using data from 1999–2006; and compared child mortality after age 
12 months in children who had received measles vaccine and those who had not using data from 1999 to 2006.
Findings The proportion of children who were fully vaccinated by 12 months of age was 53% (468 of 878) in the 2007 
cohort and 53% (467 of 879) in the 2009 cohort (relative risk [RR] 1·00, 95% CI 0·89–1·11). Coverage of DTP-3 and 
pentavalent-3 increased from 73% (644 of 878) in 2007 to 81% (712 of 879) in 2009 (RR 1·10, 95% CI 1·04 –1·17); by 
contrast, the coverage of measles vaccination declined from 71% (620 of 878) to 66% (577 of 879; RR 0·93, 0·85–1·01). 
The eﬀ ect of the changes was signiﬁ cantly diﬀ erent for DTP-3 coverage compared with measles vaccine coverage 
(p=0·002). After 12 months of age, the adjusted mortality rate ratio was 0·71 (95% CI 0·56–0·90) for children who had 
received measles vaccine compared with those who had not (0·59 [0·43–0·80] for girls and 0·87 [0·62–1·23] for boys).
Interpretation The introduction of the new vaccination programme in 2008 was associated with increased coverage 
of DTP, but decreased coverage of measles vaccine. In 1999–2006, child mortality was higher in children who had 
not received measles vaccine than in those who had.
Funding DANIDA, European Research Council, the Danish Independent Research Council, European Union FP7 via 
OPTIMUNISE, and Danish National Research Foundation.
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Introduction
The vaccination schedule in many low-income 
countries includes BCG and oral polio vaccine (OPV) at 
birth, three doses of whole-cell diphtheria-tetanus-
pertussis vaccine (DTP-3) and three doses of OPV at 6, 
10, and 14 weeks of age, and measles vaccine at 9 months 
of age.1 Just over a decade ago the GAVI Alliance began 
supporting the introduction of pentavalent (DTP plus 
hepatitis B and Haemophilus inﬂ uenzae type b antigens) 
and yellow fever vaccines in many low-income 
countries, and within the past few years has also 
supported the introduction of pneumococcal and 
rotavirus vaccines. Vaccine coverage is normally 
assessed at 12 months of age,2 and coverage for DTP-3 is 
usually used as the main performance indicator for a 
vaccine programme.3–6 The focus on DTP-3 as the 
performance indicator has meant that DTP-3 coverage 
has increased—eg, 58% of African countries had 
higher coverage for measles vaccine than for DTP-3 in 
1985, but in 2009 this had changed to 68% having a 
higher coverage for DTP-3 than for measles vaccine.1
In addition to providing protection against the targeted 
disease, vaccines used in child health programmes aﬀ ect 
the susceptibility to other pathogens, with eﬀ ects on 
mortality.7 WHO’s Strategic Advisory Group of Experts 
(SAGE) on immunisation has reviewed these so-called 
non-speciﬁ c eﬀ ects of vaccines and recommended 
further research.8,9 In brief, many observational studies 
and randomised trials have shown that measles vaccine 
as the most recent vaccination is associated with a 
marked reduction in child mortality—a reduction that is 
considerably larger than can be explained by prevention 
of measles infection alone.10–14 DTP as the most recent 
vaccination does not seem to have similar beneﬁ cial non-
speciﬁ c eﬀ ects.15–18 We postulate that if the focus on 
DTP-3 has lowered the proportion of children who have 
had measles vaccine as their most recent vaccination, it 
might have had a detrimental eﬀ ect on child health.14,19
Lancet Glob Health 2014; 
2: 478–87
Bandim Health Project, 
INDEPTH Network, Bissau, 
Guinea-Bissau (A B Fisker PhD, 
L Hornshøj MD, A Rodrigues PhD, 
I Balde BSc, M Fernandes, 
Prof C S Benn DMSc, 
Prof P Aaby DMSc); and 
Research Center for Vitamins 
and Vaccines (CVIVA), Bandim 
Health Project, Statens Serum 
Institut, Copenhagen, 
Denmark (A B Fisker, 
Prof C S Benn, Prof P Aaby)
Correspondence to:
Dr Ane Bærent Fisker, Research 
Center for Vitamins and Vaccines 
(CVIVA), Bandim Health Project, 
Statens Serum Institut, 
2300 Copenhagen S, Denmark
a.ﬁ sker@bandim.org
Articles
e479 www.thelancet.com/lancetgh   Vol 2   August 2014
To reach the ambitious goal of 90% national vaccination 
coverage by 2010, WHO has joined forces with several other 
organisations—GAVI in particular—to improve vaccination 
coverage.20 By 2010, GAVI had funded the introduction of 
the pentavalent vaccine in 59 countries w orldwide.4 Also, as 
part of GAVI’s performance-based funding, GAVI funds 
were distributed as a ﬁ nancial reward to countries in which 
DTP-3 coverage exceeded the targeted level.21
In 2008, Guinea-Bissau received support from GAVI to 
replace DTP with pentavalent vaccine, and yellow fever 
vaccine was introduced to be given together with measles 
vaccine. The introduction was accompanied by support for 
outreach strategies to supplement the routine vaccination 
services at health centres.22 Furthermore, emphasis was 
increased on the strengthening and standardisation of the 
performance statistics for coverage by 12 months of age, 
and for wastage,23 which led to a greater focus on not 
wasting doses of vaccines. For example, when pentavalent 
and yellow fever vaccines were introduced, the Expanded 
Program on Immunizations (EPI) in Guinea-Bissau 
aimed to reduce wastage for the ten-dose measles vaccine 
(and yellow fever) vials from 40% to 25%.23 Contrary to 
WHO recommendations,24 the national EPI therefore 
implemented a policy of not opening a ten-dose vial of the 
live attenuated measles or yellow fever vaccine (which have 
to be discarded 6 h after reconstitution) unless six or seven 
children were present to receive the vaccine. Between 
October, 2008, and November, 2009, we interviewed 
87 EPI managers and nurses responsible for vaccination in 
the areas of Guinea-Bissau surveyed by the Bandim Health 
Project about how many children were required for them 
to open a ten-dose measles vaccine vial. The median 
number was six children (IQR ﬁ ve to eight; unpublished 
data). In practice, this policy means that measles vaccine 
was not given during all outreach sessions; instead, 
mothers were asked to take their child to a health centre 
for vaccination or to come to a later outreach session, 
where enough children might be present to open a vial. 
Furthermore, practice changed in 2008 so that children in 
Guinea-Bissau were not given EPI vaccines after 12 months 
of age because they were outside the target group and 
vaccines given to them would count as waste. Therefore, 
children have only 3 months, between the ages of 9 and 
11 months, to receive measles vaccine. Both DTP (ten-dose 
vials of inactivated vaccine, which can be kept open for up 
to 28 days), and pentavalent vaccines (single-dose vial) 
were opened if only one child was present.
In this study, we assessed the eﬀ ect of these changes in 
the vaccination practices associated with the introduction 
of new vaccines on vaccination timeliness and coverage in 
rural Guinea-Bissau, and the potential implications for 
child survival.
Methods
Study design and participants
This study was an observational cohort study that used 
data from the Bandim Health Project (BHP), which 
monitors mortality and vaccination coverage in a health 
and demographic surveillance system in Guinea-Bissau.10 
Within this system, BHP follows 182 randomly selected 
geographic clusters initially consisting of 100 women of 
fertile age and their children in rural Guinea-Bissau. The 
clusters were selected using methods recommended by 
the EPI for surveys of immunisation coverage; 20 clusters 
of 100 women in each of the eight larger health regions 
have been sampled, and ten and 12 clusters in the 
two smallest regions. 100 clusters have been under 
surveillance since 1990, and the remaining 82 were added 
in 2006. Clusters are visited every 6 months and all 
pregnancies, births, deaths, and migrations are recorded 
at these visits. The cohort followed up in the clusters is 
open: new children and women enter when they take up 
residence in the area, are born, or become of fertile age. 
When a new woman is registered, information about age, 
ethnicity, and schooling is obtained. At all visits, a record 
is made of children’s nutritional status (by measurement 
of mid-upper-arm circumference), whether the child has a 
vaccination card, whether the card was seen, and the dates 
of all vaccinations. Since September, 2007, the BHP teams 
have been accompanied by a nurse who oﬀ ers vaccinations 
to children who are missing routine vaccines; a vaccination 
card is provided to children who do not yet have a card.
Separate ethical approval was not necessary for this 
study because the observational data was derived from 
the demographic surveillance system that has been in 
place since 1990 at the request of the Guinea-Bissau 
Ministry of Health.
Procedures
To assess the eﬀ ect of policy changes for the coverage of 
diﬀ erent vaccines, we used three diﬀ erent approaches: 
ﬁ rst, we used data from all 182 clusters under surveillance 
by the BHP in 2007 (before the introduction of new 
vaccines) and in 2009 (after the introduction) to assess 
how increased outreach services aﬀ ected coverage; 
second, we used data from 1999 to 2006 from the 
100 clusters followed up since 1990 (before the change in 
programme) to assess the proportion of children who 
received measles vaccine after 12 months of age during 
this period; and third, using data from 1999 to 2006, we 
compared survival after 1 year of age in children who had 
received measles vaccine versus those who had not.
To assess vaccination coverage, we selected two cohorts 
of children. The 2007 cohort consisted of children born 
between January and April, 2007, thus reaching 
12 months of age before the introduction of the new 
vaccines (in September, 2008) and before a shortage of 
DTP vaccines occurred (in May, 2008, the stock of DTP 
ran out and the introduction of the new vaccines was 
delayed until September, 2008, because of a shortage of 
petroleum for refrigerators, which interrupted the cold 
chain). The 2009 cohort consisted of children born in the 
same geographical clusters between January and 
April, 2009, who were eligible to receive the new vaccines 
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ﬁ nanced through GAVI. In the two southern regions of 
Guinea-Bissau (Tombali and Quinara), another research 
organisation aimed to ensure full vaccination coverage 
in selected villages by doing monthly mobile clinics.25 
This approach was not representative of the national 
programme; therefore, children living in these villages 
were excluded from the assessment of coverage.
To assess vaccination coverage by 12 months of age as 
done in EPI surveys, we used vaccine information 
obtained from children aged 12–23 months. Since the 
national policy was to provide vaccines only to children 
aged younger than 12 months, we considered only doses 
received before 12 months, even though BHP had 
vaccinated older children. Thus the denominator was 
the number of children with a vaccination card seen 
between the ages of 12 and 23 months and the numerator 
was the number of children having received a given 
vaccine by age 12 months. Similarly, of children whose 
vaccination card was not seen between the ages of 12 and 
23 months, we assessed vaccination coverage by 
12 months of age in those who had a vaccination card 
inspected between the ages of 24 and 35 months. We did 
not use recall data for children for whom a vaccination 
card was not seen within the relevant time periods; when 
the card could not be seen it was nearly always because 
the mother was not present.
Key vaccine coverage outcomes were the proportion of 
children who were fully vaccinated (ie, had received 
BCG, three doses of OPV and DTP or pentavalent 
vaccine, and measles vaccine before 12 months of age); 
vaccination coverage and median age of vaccination for 
all vaccines received before 12 months of age except for 
yellow fever, which was only given in the 2009 cohort; 
and the proportion of children who received the same 
vaccine on a speciﬁ c day within a village (since the policy 
of opening a ten-dose vial only when six to seven children 
were present would lead to more children within a given 
village returning to receive the same vaccination on the 
same day).
To assess how the policy of not providing measles 
vaccine after 12 months of age aﬀ ected overall measles 
vaccine coverage, we used data from the 100 village 
clusters followed up since 1990. A civil war occurred in 
1998, and in late May, 2006, a 2-week national measles 
vaccine campaign targeted all children aged between 
6 months and 15 years; therefore, we used data from 
January, 1999, to May, 2006. We assessed measles vaccine 
coverage by age 12 months, 24 months, and 36 months in 
the 1999–2006 cohort, which consisted of children who 
had their vaccination card inspected between Jan 1, 1999, 
and May 15, 2006, when they were aged 12–23 months, 
24–35 months, and 36–47 months, respectively.
To assess the eﬀ ect of measles vaccine on child mortality, 
we used data from 1999 to 2006 to compare survival of 
children who had received measles vaccine with those 
who had not. Since 2007, BHP has provided vaccines after 
infancy as part of a vitamin A supplementation trial 
(NCT00514891); therefore, children who had not been 
vaccinated against measles received measles vaccine from 
the BHP team after 12 months of age, even though it was 
national EPI policy not to vaccinate after this age,26 hence 
later cohorts could not contribute to this analysis. Children 
aged 12–35 months who had their vaccination card 
inspected between Jan 1, 1999, and May 15, 2006, were 
included in the survival analysis.
Statistical analyses
In our analyses of vaccination coverage before and after 
the change in vaccination programme, we compared the 
2009 cohort with the 2007 cohort as a reference. We 
compared the distribution of background variables in the 
two cohorts by Fisher’s exact test, rank-sum test, and the 
t test, analysed vaccination coverage by calculating 
relative risks using binomial regression adjusted for 
clustering by robust variance estimates (no convergence 
problems were encountered), and assessed distribution 
of age at vaccination by rank-sum test.
In our analyses of survival of children who had been 
vaccinated against measles compared with those who 
had not, children from the 1999–2006 cohort entered the 
analysis when they had their vaccination card inspected 
(landmark approach).27 As in a previous study of child 
survival using data from BHP,10 follow-up was censored 
at the subsequent visit, or 6 months later if the 
subsequent visit occurred more than 6 months after the 
previous visit. Follow-up was stopped on May 15, 2006, 
because the national measles vaccine campaign began.
We used a Cox proportional-hazards model with age 
as underlying time to compare mortality rates between 
children who had and had not received measles vaccine, 
stratiﬁ ed for village cluster. Estimates are presented as 
crude ratios and are also adjusted for ethnicity, maternal 
age, and schooling. We assessed interaction between 
measles vaccination status and sex using Wald statistics. 
We assessed the proportional hazards assumption by 
Figure 1: Description of the 2007 and 2009 cohorts
*Children living in villages where a research project provided all health interventions.
1398 children who were born between Jan 1 and 
April 30, 2007, were resident in the area at 
12 months of age
2007 cohort
164 excluded*
1234 eligible
878 available for analysis
356 excluded (vaccination card not 
seen between the ages of 
1 and 2 years)
1303 children who were born between Jan 1 and 
April 30, 2009, were resident in the area at 
12 months of age
2009 cohort
117 excluded*
1186 eligible
879 available for analysis
307 excluded (vaccination card not 
seen between the ages of 
1 and 2 years)
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log-log plots and Schoenfeld residuals. We analysed 
data using Stata (version 11.2).
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, or writing of the report. The corresponding 
author had full access to all the data in the study, and had 
ﬁ nal responsibility for the decision to submit for 
publication.
Results
For assessment of vaccination coverage, we followed up 
1398 children born between January and April, 2007, and 
1303 born between January and April, 2009. We excluded 
164 children from the 2007 cohort and 117 children from 
the 2009 cohort because they lived in the villages with 
monthly outreach clinics,25 leaving 1234 children in the 
2007 cohort and 1186 in the 2009 cohort (ﬁ gure 1). We 
assessed vaccination coverage in children whose 
vaccination card was seen between the ages of 12 and 
23 months: 878 (71%) of 1234 children in the 2007 cohort 
had their vaccination card seen during this period 
compared with 879 (74%) of 1186 children in the 2009 
cohort. The main reason for not seeing a vaccination 
card between the ages of 12 and 23 months was that the 
mother was not present; at 847 (88%) of the 965 visits 
made to the 663 children for whom a vaccination card 
was not seen, the mother was not present.
The distribution of background variables for the two 
cohorts is shown in table 1. Nutritional status, measured 
by mid-upper-arm circumference, was slightly lower in 
the 2009 cohort than in the 2007 cohort; however, the 
diﬀ erence of 1 mm is unlikely to be clinically signiﬁ cant.
The proportion of fully vaccinated children was the 
same in the two cohorts: 53% (468 of 878) in the 2007 
cohort and 53% (467 of 879) in the 2009 cohort (table 2). 
The coverage for individual antigens varied. Coverage of 
DTP-3 increased signiﬁ cantly from 73% (644 of 878) in 
the 2007 cohort to 81% (712 of 879) in the 2009 cohort 
(table 2). The increase in coverage was due to more 
children beginning their DTP vaccination series and to a 
lower dropout rate: in the 2007 cohort, 824 (94%) of 
children received DTP-1, but 234 (27%) did not receive 
DTP-3, whereas in 2009, 862 (98%) received DTP-1, and 
167 (19%) did not receive DTP-3. Hence, the RR for 
dropout was 0·71 (95% CI 0·59–0·86). In parallel, the 
median age of children when they received each dose of 
DTP declined signiﬁ cantly (table 2).
Despite the improvement in DTP-3 coverage, the 
median age at measles vaccination increased signiﬁ cantly 
2007 cohort (n=878) 2009 cohort (n=879) p value*
Child characteristics
Male sex 428 (49%) 436 (51%) 0·74
Age at interview, months 19·5 (16·6–22·0) 19·5 (16·8–21·7) 0·80†
Mid-upper-arm circumference, mm 144 (13) 143 (12) 0·005‡
Maternal characteristics
Age, years 27·5 (22·5–32·6) 27·0 (22·4–32·1) 0·15†
Any formal education 201 (23%) 221 (26%) 0·29
Ethnicity ·· ·· 0·12
Balanta 176 (20%) 171 (19%) ··
Fula 200 (23%) 212 (24%) ··
Mandinga 175 (20%) 213 (24%) ··
Pepel 125 (14%) 97 (11%) ··
Manjaco or Mancanha 73 (8%) 61 (7%) ··
Other or unknown 129 (15%) 125 (14%) ··
Data are number (%), median (IQR), or mean (SD). Information was missing for some children: 50 children in the 2007 
cohort and 37 in the 2009 cohort did not have their mid-upper-arm circumference measured; for 15 and 11 children, 
respectively, no information about maternal age could be obtained; and for 18 and 18 children, respectively, no 
information about maternal education could be obtained. *Distributions compared by Fisher’s exact tests unless 
stated otherwise. †Distributions compared by rank-sum test. ‡Distributions compared by t test.
Table 1: Background variables in the 2007 and 2009 cohorts for children whose vaccination cards were 
seen between the ages of 12 and 23 months
Vaccination coverage, n (%) Median age at vaccination, days (IQR)
2007 cohort
(n=878)
2009 cohort
(n=879)
Relative risk
(95% CI)*
2007 cohort
(n=878)
2009 cohort
(n=879)
p value†
Fully vaccinated‡ 468 (53%) 467 (53%) 1·00 (0·89–1·11) NA NA NA
BCG 780 (89%) 801 (91%) 1·03 (0·99–1·07) 44 (15–101) 35 (17–65) 0·001
DTP-1 or pentavalent-1 824 (94%) 862 (98%) 1·04 (1·02–1·07) 74 (53–126) 65 (51–90) <0·0001
DTP-2 or pentavalent-2 753 (86%) 825 (94%) 1·09 (1·04–1·14) 141 (98–201) 116 (93–162) <0·0001
DTP-3 or pentavalent-3 644 (73%) 712 (81%) 1·10 (1·04–1·17) 192 (141–246) 168 (133–223) 0·001
OPV-1 823 (94%) 865 (98%) 1·05 (1·02–1·08) 76 (53–126) 64 (50–90) <0·0001
OPV-2 740 (84%) 822 (94%) 1·11 (1·06–1·16) 141 (97–200) 119 (93–167) <0·0001
OPV-3 596 (68%) 689 (78%) 1·15 (1·08–1·24) 187 (139–246) 176 (135–240) 0·14
Measles vaccine 620 (71%) 577 (66%) 0·93 (0·85–1·01) 290 (275–314) 299 (278–322) 0·002
NA=not applicable. DTP=diphtheria-tetanus-pertussis vaccine. Pentavalent=diphtheria-tetanus-pertussis plus Haemophilus inﬂ uenzae type b plus hepatitis B vaccine. 
OPV=oral polio vaccine. *2009 vs 2007; adjusted for clustering by robust variance estimates. †Analysed by rank-sum test. ‡Received BCG, three doses of DTP or pentavalent 
vaccine, three doses of OPV, and measles vaccine by 12 months of age.
Table 2: Vaccination coverage by 12 months of age and median age at vaccination for children in the 2007 and 2009 cohorts whose vaccination cards 
were seen between the ages of 12 and 23 months
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between 2007 and 2009 (table 2). The proportion of 
children who had received measles vaccine by 12 months 
of age thus declined slightly from 620 (71%) children in 
the 2007 cohort to 577 (66%) in the 2009 cohort (table 2). 
The eﬀ ect of the vaccine programme change on DTP-3 
coverage was signiﬁ cantly diﬀ erent from the eﬀ ect on 
measles vaccine coverage (pinteraction=0·002). Coverage of all 
vaccines did not diﬀ er between boys and girls (data not 
shown).
The BHP teams started providing DTP and measles 
vaccine in September, 2007. BHP teams vaccinated more 
children in the 2009 cohort than in the 2007 cohort 
(appendix). Excluding children vaccinated by the BHP 
team, more children in the 2009 cohort received DTP-3 
than did those in the 2007 cohort (RR 1·07, 
95% CI 1·00–1·14), whereas fewer children in the 2009 
cohort received measles vaccine than did those in the 2007 
cohort (RR 0·91, 0·83–1·00; p=0·002 for the diﬀ erential 
eﬀ ect for DTP-3 and measles vaccine coverage; appendix).
For children with a vaccination card seen only between 
the ages of 24 and 35 months, 83 (62%) of 133 children 
had received DTP-3 by 12 months of age in the 2007 
cohort compared with 93 (66%) of 140 in the 2009 cohort; 
measles vaccine coverage by 12 months of age was 47% in 
both cohorts (62 of 133 children in the 2007 cohort and 66 
of 140 children in the 2009 cohort). 1011 (82%) of the 
1234 children in the 2007 cohort had a vaccination card 
that was seen between the ages of 12 and 35 months 
compared with 1019 (86%) of the 1186 children in the 
2009 cohort. In these children, DTP-3 coverage increased 
from 71% (717 of 1011) in the 2007 cohort to 79% (805 of 
1019) in the 2009 cohort (RR 1·10, 95% CI 1·04–1·17) and 
measles vaccine coverage declined from 67% (682 of 
1011) in 2007 to 63% (643 of 1019) in 2009 (RR 0·93, 
95% CI 0·85–1·01; p=0·0002 for the diﬀ erential eﬀ ect 
for DTP-3 and measles vaccine coverage).
In the children who had received measles vaccine 
before age 12 months, the proportion who received 
measles vaccine on the same day as at least one other 
child in the same cluster was 48% (298 of 620) in the 
2007 cohort and 57% (331 of 577) in the 2009 cohort 
(RR 1·19, 95% CI 1·03–1·37). By contrast, the frequency 
of same-day administration of DTP-3 was unchanged: of 
the children who received DTP-3, 305 (47%) of 
644 children in the 2007 cohort and 320 (45%) of 712 in 
the 2009 cohort received DTP-3 at the same time that 
another child in the same village received DTP-3 
(RR 0·95, 95% CI 0·82–1·09).
Although we noted only a small decline in measles 
vaccine coverage by 12 months of age between 2007 and 
2009 (table 2), total measles vaccine coverage has declined 
further because measles vaccine also used to be given 
after 12 months of age. In the 12 119 children in the 
1999–2009 cohort whose vaccination card was seen when 
aged 12–35 months, 6479 (53%) had received measles 
vaccine by 12 months of age. Of the children whose card 
was seen between the ages of 24 and 35 months, 
6359 (83%) of 7642 had received measles vaccine by 
24 months of age, and of those whose card was seen 
between the ages of 36 and 47 months, 4221 (92%) of 4589 
had received measles vaccine by 36 months of age (table 3). 
Hence, of the 5640 (47%) children in the 1999–2006 
Measles vaccine coverage
All children in the 1999–2006 mortality cohort n=12 119
Measles vaccine by age 12 months 6479 (53%)
Measles vaccine after age 12 months* 9231 (76%)
Card seen between 24–35 months n=7642
Measles vaccine by age 24 months 6359 (83%)
Card seen between 36–47 months n=4589
Measles vaccine by age 36 months 4221 (92%)
Children with no measles vaccine by age 12 months n=5640
Card seen between 24–35 months n=3663
Measles vaccine by age 24 months 2380 (65%)
Card seen between 36–47 months n=2279
Measles vaccine by age 36 months 1911 (84%)
*Recorded at the ﬁ rst instance that the vaccination card was seen.
Table 3: Measles vaccination coverage in 1999–2006 mortality cohort
Figure 2: Description of the 1999–2006 cohort.
18 119 children were followed up when aged 
12–35 months between 1999 and 2006 
17 719 followed up after first visit after 12 months 
between 1999 and 2006
12 119 had vaccination card seen when aged 
12–35 months between 1999 and 2006
5600 excluded (no vaccination card was seen 
between the ages of 12 and 35 months)
400 were excluded
129 moved at first visit between ages 
12–35 months
258 dead at first visit between 12–35 months
13 no visit between 12–35 months 
6949 had vaccination card seen when 
aged 12–17 months
6371 had vaccination card seen when 
aged 18–23 months
5801 had vaccination card seen when 
aged 24–29 months
4623 had vaccination card seen when 
aged 30–35 months
1914 (27%) had not received measles vaccine
5032 (72%) had received measles vaccine
1057 (17%) had not received measles vaccine
5314 (83%) had received measles vaccine
710 (12%) had not received measles vaccine
5091 (88%) had received measles vaccine
439 (10%) had not received measles vaccine
4184 (90%) had received measles vaccine
See Online for appendix
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cohort who had not received measles vaccine by 12 months 
of age, 2279 (40%) had a card inspected between the ages 
of 36 and 47 months, of whom 1911 (84%) had received 
measles vaccine by age 36 months.
Of the 18 119 children aged 12–35 months at surveillance 
rounds in 1999–2006, 12 119 (67%) had had their 
vaccination card inspected (ﬁ gure 2). During the 
6 months after vaccine card inspection, children who had 
been vaccinated against measles had signiﬁ cantly lower 
mortality than did those who were not vaccinated against 
measles (table 4; ﬁ gure 3). The lower mortality in the 
measles-vaccinated group was mainly due to girls who 
had received measles vaccine having a lower mortality 
than girls who had not (table 4; pinteraction=0·07).
Mothers of children who had received measles vaccine 
were slightly younger and more likely to come from the 
Muslim ethnic groups Fula and Mandinga than from 
other ethnic groups; maternal education was not 
associated with measles vaccination (appendix). 
Adjusting for these background variables had little 
eﬀ ect on the mortality rate ratios [MRRs], the overall 
adjusted MRR being 0·71 (95% CI 0·56–0·90; table 4). 
The mid-upper-arm circumference was larger in 
children who had received measles vaccine than in those 
had not, possibly owing to a beneﬁ cial eﬀ ect of measles 
vaccine on morbidity (intermediate variable), but also 
possibly due to health status before vaccination, which 
might have aﬀ ected whether a child was vaccinated or 
not. When we adjusted for mid-upper-arm circumference 
as well, the MRR for measles-vaccinated children was 
0·73 (95% CI 0·58–0·94) overall, 0·62 (0·45–0·85) in 
girls, and 0·90 (0·63–1·28) in boys.
Compared with children who had not received measles 
vaccine, the children who received measles vaccine after 
12 months of age had an MRR of 0·67 (95% CI 0·53–0·86); 
the MRR was 0·56 (0·41–0·78) for girls and 
0·83 (0·58–1·19) for boys (data not shown).
11 deaths were reported to be due to measles in ﬁ ve girls 
(two who had received measles vaccine and three who 
had not) and six boys (three who had received measles 
vaccine and three who had not). Censoring these deaths, 
the MRR was 0·75 (95% CI 0·59–0·95) overall, 
0·62 (0·45–0·84) for girls, and 0·95 (0·67–1·36) for boys. 
Censoring deaths that occurred from May, 2003, to 
May, 2004, when Guinea-Bissau had a measles epidemic28 
removed 79 deaths (in 11 children who had not received 
measles vaccine and 68 who had) and resulted in an 
MRR of 0·72 (95% CI 0·57–0·90).
Number of 
observations*
Mortality rate per 1000 PYRS
(deaths/PYRS)
Mortality rate ratio
(95% CI)†
Adjusted mortality rate ratio
(95% CI)‡
All children ·· ·· 0·72 (0·57–0·90) 0·71 (0·56–0·90)
Measles unvaccinated§ 4120 (17%) 56·7 (103/1816) ·· ··
Measles vaccinated 19 621 (83%) 41·3 (358/8665) ·· ··
Girls ·· ·· 0·59 (0·44–0·80) 0·59 (0·43–0·80)
Measles-unvaccinated 2060 (18%) 66·3 (60/906) ·· ··
Measles-vaccinated 9636 (82%) 40·7 (173/4256) ·· ··
Boys ·· ·· 0·89 (0·63–1·26) 0·87 (0·62–1·23)
Measles-unvaccinated 2060 (17%) 47·3 (43/910) ·· ··
Measles-vaccinated 9985 (83%) 42·0 (185/4409) ·· ··
Age when vaccination card was inspected
12–17 months ·· ·· 0·74 (0·52–1·05) 0·76 (0·53–1·09)
Measles-unvaccinated 1914 (28%) 56·3 (48/852) ·· ··
Measles-vaccinated 5032 (72%) 45·8 (102/2229) ·· ··
18–23 months ·· ·· 0·64 (0·42–0·97) 0·61 (0·40–0·93)
Measles-unvaccinated 1057 (17%) 67·1 (31/462) ·· ··
Measles-vaccinated 5314 (83%) 43·8 (103/2349) ·· ··
24–29 months ·· ·· 0·72 (0·43–1·21) 0·70 (0·42–1·18)
Measles-unvaccinated 710 (12%) 58·3 (18/309) ·· ··
Measles-vaccinated 5091 (88%) 42·4 (95/2241) ·· ··
30–35 months ·· ·· 0·98 (0·41–2·33) 0·96 (0·40–2·28)
Measles-unvaccinated 439 (10%) 31·1 (6/193) ·· ··
Measles-vaccinated 4184 (90%) 31·4 (58/1846) ·· ··
PYRS=person-years of observation. DTP=diphtheria-tetanus-pertussis vaccine. OPV=oral polio vaccine. *Eg, a child whose vaccination card was inspected two times between 
12 and 35 months contributes two non-overlapping periods of observation. †Stratiﬁ ed by village cluster. ‡Stratiﬁ ed by village cluster and adjusted for ethnicity, maternal age 
in quartiles, and schooling. §At 3563 (86%) of 4120 observations for children who had not received measles vaccine the child had received one or more other vaccines; for 
2810 (79%) of these 3563 observations the child had received DTP as the most recent vaccine (2200 [78%] had received DTP or DTP plus OPV as their most recent vaccine 
and 610 [22%] had received DTP with BCG).
Table 4: Mortality for children according to whether or not they had received measles vaccine between 1999 and 2006
Articles
www.thelancet.com/lancetgh   Vol 2   August 2014 e484
If no measles vaccines had been given after 12 months 
of age in the 1999–2006 cohort, 4926 (47%) of 
10 481 person-years of observation (appendix) would have 
been lived without measles vaccination between 12 and 
36 months of age, rather than 1816 (17%) person-years of 
observation. On the basis of the beneﬁ cial eﬀ ect of 
measles vaccine on all-cause mortality that we have 
reported, vaccination after 12 months of age saved 
40 (8%) of 501 deaths in the cohort in children aged 
1–3 years. For girls this reduction in mortality was 11% 
(30 of 263) and for boys it was 4% (ten of 238).
Discussion
The introduction of new vaccines in Guinea-Bissau in 
2008 was accompanied by not only intensiﬁ ed outreach 
vaccination services, but also reinforced wastage 
policies, including not oﬀ ering vaccinations to children 
older than 12 months and only opening multidose vials 
with live attenuated vaccines when more than half of 
the doses could be used. As expected, better outreach 
services increased coverage and timeliness of 
pentavalent vaccinations. However, the median age of 
measles vaccination increased and the measles vaccine 
coverage at 12 months of age dropped from 71% to 66%. 
Before the change in the vaccination programme, 84% 
of unvaccinated children received measles vaccine 
between the ages of 12 months and 35 months. Had this 
trend continued, 95% would have received measles 
vaccine by 36 months of age in the 2009 cohort. Hence, 
the fact that measles vaccine is no longer provided after 
12 months of age might make an increasing proportion 
of children susceptible to measles infection.
This ﬁ nding might also have more far-reaching 
outcomes, because even when measles deaths were 
censored, children who had received measles vaccine 
had a lower risk of mortality than did children who had 
not received the vaccine, and the beneﬁ t was particularly 
marked for girls. Hence, a decline in total measles 
vaccine coverage might lead to an increase in overall 
child mortality, particularly for girls.
The continuous demographic surveillance done by the 
BHP teams is likely to provide better information from a 
more representative selection of the population than that 
provided by many EPI vaccination surveys, for which the 
reliability of techniques used to select random samples of 
the population has been questioned.29 However, the 
6-monthly inspection of vaccination cards might remind 
mothers to get their children vaccinated, resulting in 
higher vaccination coverage than in the source population.
We used vaccination cards seen during routine visits to 
establish vaccination status. However, by not including 
children whose vaccination cards were not inspected, we 
might have overestimated vaccine coverage. Maternal 
absence (often because they were travelling) was the 
main reason for not being able to inspect a vaccination 
card. The children whose vaccination cards were not 
seen between the ages of 12 and 24 months were 
travelling more and their vaccination coverage was lower 
than those whose cards were seen at ages 12–24 months, 
as shown by the lower coverage in children seen only 
after 24 months of age. However, the relative changes in 
DTP-3 coverage and measles vaccine coverage remained 
the same when children whose vaccination cards were 
not seen between 12 and 23 months but were seen after 
24 months of age were included in the analysis.
To create comparable cohorts, we excluded children 
who were exposed to extended vaccine shortages. Hence, 
we only included children born during a 4-month 
window. BHP started vaccinating during biannual visits 
after September, 2007. The 2009 cohort therefore had the 
opportunity to be vaccinated by the BHP team at all visits 
during their ﬁ rst year of life, whereas the 2007 cohort was 
not vaccinated by the BHP team at their ﬁ rst visit in 2007. 
When children vaccinated by the BHP were excluded 
from our analysis, the rise in DTP-3 coverage between 
2007 and 2009 was slightly lower, but the fall in measles 
vaccine coverage was stronger than when those children 
were included in the analysis. Hence, the BHP provision 
of vaccines might have lessened the decline in measles 
vaccine coverage. Irrespective of whether we used data 
from all children or only those who had not received 
vaccines from the BHP team, we noted a signiﬁ cant 
diﬀ erential eﬀ ect for DTP-3 and measles vaccine 
(appendix). According to WHO ﬁ gures, Guinea-Bissau 
reported a 1-month measles vaccine shortage in 2008, 
and shortages of H inﬂ uenzae type b and hepatitis B 
vaccines of 1–2 months in 2009.30 However, these 
shortages do not explain the diﬀ erences in the vaccination 
coverage patterns for DTP-3 and measles vaccine; a 
shortage of measles vaccine in 2008 would reduce the 
measles vaccine coverage in the 2007 cohort and a 
shortage of pentavalent vaccines in 2009 would have 
lowered the pentavalent coverage in the 2009 cohort, and 
hence the shortages, if anything, would have reduced the 
reported diﬀ erential trends in coverage.
Figure 3: Mortality of children according to measles vaccination status
Includes children who received measles vaccine after 12 months of age; children 
contributed an observation time after card inspection (at which they were classiﬁ ed 
as vaccinated or unvaccinated) and stayed in the analysis for the next 6 months.
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The analysis of mortality—comparing children who 
received measles vaccine with those who did not—is 
observational, and a self-selection bias and diﬀ erential 
access to vaccination might have also contributed to the 
reported diﬀ erence. However, by stratifying for cluster, 
mortality in children who had and had not received 
measles vaccine was compared within the same village. 
Furthermore, adjusting for other background variables 
had little eﬀ ect on the estimates. We used a landmark 
approach, in which children did not change vaccination 
status on the date of vaccination, but on the date that the 
information was obtained. This method prevents survival 
bias due to better vaccination information for survivors 
and provides conservative estimates of the diﬀ erence in 
mortality between vaccinated and unvaccinated children.27
In line with the observational data presented here, 
randomised trials have shown major reductions in 
mortality not related to the prevention of measles 
infection, and the beneﬁ cial eﬀ ect has been stronger for 
girls than for boys.11,12,31 The recent SAGE review concluded 
that measles vaccine seemed to have stronger beneﬁ cial 
eﬀ ects for girls than for boys.8 In our study, the strongest 
beneﬁ cial eﬀ ect was also observed in girls. The eﬀ ect was 
slightly stronger for children who had received their 
measles vaccine after 12 months of age and thus were 
closer to starting the observation period. If selection bias 
had explained the beneﬁ cial eﬀ ect of measles vaccine after 
12 months of age, the survival beneﬁ t should be strongest 
for the children vaccinated before 12 months of age.
Despite the huge investments in improving vaccination 
coverage, few studies have assessed the eﬀ ects of donor 
support; all studies have focused on DTP-3 coverage and 
none have reported measles vaccine coverage.32–37 Higher 
DTP-3 than measles vaccine coverage has been described 
in other cohorts3,38,39 and, as mentioned, 58% of African 
countries had higher measles vaccine coverage than 
DTP-3 coverage in 1985, whereas 68% had a higher 
coverage for DTP-3 than for measles vaccine in 2009.1 A 
report of vaccine coverage from 2008 suggested that 
5 million children in Africa had not received DTP-3, but 
7·5 million had not received measles vaccine.38
Children who receive measles vaccine have 
consistently had lower mortality than children who 
have not received the vaccine, when compared with 
unvaccinated children and when compared with those 
who have received DTP, both in observational 
studies10,13 and randomised trials (panel).11,12 In 1990–96, 
when overall child mortality was higher in rural 
Guinea-Bissau than it was in our present study, we 
undertook a similar study in children aged 7–13 months, 
in the same village clusters as we used in this study. 
During the 6 months after vaccination card inspection, 
children who had received measles vaccine had a lower 
risk of mortality than did children who had not received 
measles vaccine (adjusted mortality ratio 0·48, 
95% CI 0·27–0·87).10
The increase in DTP-3 coverage from 73% to 81% 
between 2007 and 2009 and the addition of hepatitis B 
and H inﬂ uenzae type b antigens are likely to have 
beneﬁ cial eﬀ ects on the prevalence of the target diseases 
from all ﬁ ve pathogens. However, despite the additional 
resources used to introduce new vaccines and achieve 
higher DTP-3 coverage, the age that children received 
measles vaccine increased and the coverage declined. 
Although the increase in the median age that children 
received measles vaccine might be explained by children 
being taken for vaccination at an older age, the fact that 
the increase in the age that children received measles 
vaccine was associated with a higher proportion of 
children receiving measles vaccine on the same day does 
suggest that the increase in age was due to the more 
restrictive policy of only opening multidose vials on 
speciﬁ c days. When only children aged younger than 
12 months are eligible, and when opening a vial requires 
the presence of six to seven children, some opportunities 
to vaccinate might be missed and the age that children 
undergo vaccination will increase. It should be 
emphasised that it is not WHO24 or GAVI policy to restrict 
measles vaccination. However, Guinea-Bissau’s proposal 
to GAVI23 and their multiyear plan for 2010–14 aimed to 
further reduce vaccine wastage;40 with a narrow wastage 
margin, programme oﬃ  cers are likely to implement 
restrictive policies for multidose vials and vaccinations 
after 12 months of age.
Hence, encouraging good programme performance 
(timely vaccinations, reduced wastage) can seemingly 
conﬂ ict with good programme outcomes (higher 
coverage), which could aﬀ ect child survival. We reported 
Panel: Research in context
Systematic review
We searched PubMed for publications on “mortality” or “death” in relation to one of the 
vaccine terms “DTP”, “DPT”, “diphtheria-tetanus-pertussis”, or “pentavalent vaccine” 
published before Dec 1, 2011, in English, French, Portuguese, Spanish, German, and 
Scandinavian languages, as described previously.15 Likewise, as described previously,14 we 
examined existing reviews and searched PubMed for studies comparing the mortality of 
children who had and had not received measles vaccine. The results of studies of 
diphtheria-tetanus-pertussis (DTP) vaccine suggest that DTP is associated with increased 
female mortality, as previously reviewed.15 By contrast, measles vaccination has been 
shown in many observational studies and randomised trials to have beneﬁ cial non-speciﬁ c 
eﬀ ects that are not explained by the prevention of measles infection.10–14 The performance 
of vaccination programmes are often assessed by the coverage of three doses of DTP 
(DTP-3).33 We postulate that the focus on DTP-3 has diminished the emphasis on measles 
vaccine, even though this vaccine is associated with improved child survival.
Interpretation
When pentavalent (DTP plus hepatitis B and Haemophilus inﬂ uenzae type b) vaccine was 
introduced into the vaccination programme in Guinea-Bissau in 2008, the age of 
vaccination declined and DTP-3 coverage increased, but simultaneously the age of 
children who received measles vaccine increased and the coverage declined. To ensure 
that the assessment of vaccination programmes is an indicator of the desired eﬀ ects on 
child survival, the coverage of measles vaccine administered after DTP-3 could be 
considered as the main performance indicator.
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that children who received the measles vaccine had a 
lower risk of mortality after 12 months of age than did 
children who did not receive the vaccine. In the 
1999–2006 cohort, mortality was also lower for children 
who received measles vaccine after 12 months of age 
than for those who did not receive it at all. As shown in 
previous studies,10,11,13 exclusion of the measles deaths in 
our study did not change the beneﬁ cial eﬀ ect. Thus the 
reduction in child mortality associated with measles 
vaccination as the most recent vaccination cannot be 
explained by prevention of measles infection alone. By 
contrast, no prospective study has shown DTP as the 
most recent vaccination to be associated with a beneﬁ cial 
non-speciﬁ c eﬀ ect.10,15–18,41 The beneﬁ cial eﬀ ect of measles 
vaccination has been strongest for girls, and results of 
some studies have suggested that DTP might have a 
negative eﬀ ect in girls.11,15,17,41,42 Hence, girls might be 
aﬀ ected more than boys from the declining measles 
vaccine coverage.
Several ways to increase measles vaccine coverage 
could be considered. First, wastage might be reduced if 
two-dose or ﬁ ve-dose vials were used instead of ten-dose 
vials; however, the measles vaccine is cheap and the per-
dose cost is lower for ten-dose vials than for single-dose 
vials if more than two doses are used from a ten-dose 
vial.43 From a public health perspective, donors should 
monitor local implementation practices to ensure that 
wastage management does not conﬂ ict with WHO 
recommendations and overrule the right of every child 
to get timely vaccination. Second, since a 3-month 
window between 9 and 11 months of age is too narrow to 
vaccinate all children against measles, especially in 
remote areas, measles vaccination after 12 months of age 
should be encouraged—eg, by also assessing coverage of 
measles vaccine at 18 or 24 months of age. Third, even 
though measles vaccine coverage is an indicator of 
progress towards Millennium Development Goal (MDG) 
4,44 changes in measles vaccine coverage have received 
little attention because DTP-3 coverage has been the 
main performance indicator for vaccination programmes 
assessed by the Global Vaccine Action Plan5 and has 
been used to establish whether or not a country is 
eligible for GAVI ﬁ nancial rewards.21 Programme 
managers have therefore encouraged activities that 
increased DTP-3 coverage. Since 2012, GAVI’s revised 
performance-based funding criteria also include measles 
vaccine: GAVI rewards countries with US$30 per 
additional child who receives measles vaccine if measles 
vaccine coverage increases, in addition to US$30 per 
child for DTP-3 coverage increases.45 This incentive is 
clearly an improvement over using only DTP-3 as a 
performance indicator, but many children might still 
receive DTP after measles vaccine, which has been 
associated with higher child mortality than for DTP 
followed by measles vaccine, particularly for girls.8,15 A 
performance indicator, such as the proportion of 
children who received measles vaccine at least 4 weeks 
after DTP-3, would be more logical, because this 
outcome is positively associated with child survival.11
Vaccines and vaccination policies are justiﬁ ed, but 
rarely assessed, in terms of their eﬀ ect on child survival. 
Results of our study suggest that the focus on DTP-3 as 
the main performance indicator and the focus on 
reducing waste in the vaccination programme might have 
had unfortunate eﬀ ects. In Guinea-Bissau, increased 
funding for outreach services improved the coverage and 
timeliness of DTP vaccination, but simultaneously the 
coverage for measles vaccine declined, leaving a third of 
children susceptible to measles infection, potentially 
hindering progress towards MDG4.
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